Engflag

Sanlein 0.1

Quick links to important sections

Sanlein 0.1

Sanlein 0.1_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sanlein 0.1

Sanlein 0.1: What It Is (Overview)

Property Description
Active ingredient Sodium Hyaluronate (0.1%)
Form Ophthalmic solution (Eye drops)
Pharmacological class Viscoelastic agent / Ophthalmic lubricant
Common use Surface lubrication and hydration
Origin Biotechnologically derived polymer

Sanlein 0.1: Identity, Form, and Pharmacological Class

Sanlein 0.1 is an ophthalmic solution (eye drop) containing Sodium Hyaluronate as its single active ingredient at a concentration of 0.1%. It is classified pharmacologically as a viscoelastic agent and a specialized ophthalmic lubricant, designed for topical administration to the eye. The product is manufactured by Santen, a company globally recognized for specializing in ophthalmology products.

The formulation is clinically recognized as a treatment to help stabilize the tear film. Sodium Hyaluronate is utilized as a moisturizing agent for the ocular surface, and these solutions are generally recognized as effective and safe for ocular lubrication. This formulation is designed to help keep the surface of the eye moist and comfortable.

What is Sodium Hyaluronate and Why is it Used?

The active component, Sodium Hyaluronate, is the salt form of Hyaluronic Acid, a substance naturally found in the human body. It is prepared through biotechnological methods, ensuring it is a physiological compound that the body recognizes well, contributing to its common use for lubrication after events like wearing contact lenses.

The substance acts as a powerful humectant because it has an exceptional ability to attract and bind water, making it ideal for continuous surface hydration. Due to its affinity for moisture, high-molecular-weight Hyaluronic Acid has excellent lubricating properties because of its viscosity and ability to adhere to the corneal surface. This confirms that the natural thickness of this medicine is key to protecting the eye.

Is Sanlein 0.1 a Simple Eye Drop or a Viscoelastic Agent?

Sanlein 0.1 is specifically known as a viscoelastic agent, which distinguishes it from simpler, low-viscosity tear substitutes. This property is a key differentiating feature of the Sanlein brand line, as it ensures the solution is not rapidly washed away and maintains an optimal layer thickness for comfort.

This viscoelastic behavior is crucial because it allows the fluid to maintain a stable, protective cushion on the eye's surface when at rest, but flows easily and smoothly when the eye blinks. The result is a more durable, stable lubricating film that provides sustained protection and better tear film retention compared to thin, non-viscoelastic solutions.

What side effects are possible with Sanlein 0.1?

Possible Side Effects and Safety Information

The official safety documentation for Sanlein 0.1, a Sodium Hyaluronate ophthalmic solution, focuses on localized reactions at the site of administration and the potential for hypersensitivity. The safety profile is defined by regulatory agencies based on localized and systemic risk.

Officially Documented Adverse Reactions

The documented adverse reactions are largely categorized under Eye disorders and related Skin and Subcutaneous Tissue Disorders, according to regulatory standards. Ocular effects listed in official product information include itching, irritation, eye discharge, eye pain, conjunctivitis, conjunctival injection (redness), and corneal surface conditions such as superficial punctate keratitis. Reactions affecting the surrounding tissue may include blepharitis (eyelid inflammation) and eyelid dermatitis.

Most of these effects are reported to occur at a low frequency or rarely based on post-marketing surveillance data, indicating the limited occurrence of these events in clinical practice.

Serious Reactions and Safety Constraints

A key safety constraint documented in regulatory labeling is the condition of hypersensitivity to the active ingredient, Sodium Hyaluronate, or to any of the solution's excipients. The medicine is formally contraindicated and should not be administered to patients with a known history of such an allergy.

Although rare, the potential for serious adverse reactions involves the manifestation of a severe Hypersensitivity Reaction (allergic response). This may include systemic signs or severe local effects, such as a distinct change in eyesight or severe eye irritation.

Population-Specific Safety

The safety of the ophthalmic solution has not been definitively established for use during pregnancy or in women who are breastfeeding. Administration in these populations should only occur when the anticipated therapeutic benefit is determined to outweigh any potential risk, based on a prescriber's assessment.

Overdose and Emergency Response

The official regulatory information for Sodium Hyaluronate ophthalmic solution (Sanlein 0.1) provides specific guidance regarding overdose and mandated help-seeking actions. Since this medicine is a topical viscoelastic agent applied directly to the ocular surface, severe systemic toxicity following topical overdose is not anticipated by regulatory authorities. This assessment is based on the substance's properties, which lead to minimal systemic absorption, and the expectation that any excess fluid will naturally flow from the eye.

Overuse of the drops may produce localized clinical manifestations, such as increased redness or irritation of the eye. Management of these effects is generally supportive.

The most serious regulatory concern is accidental ingestion of the solution. Official labeling strictly mandates that if the product is swallowed, professional medical assistance must be sought, or a Poison Control Center must be contacted immediately. There is no specific antidote documented for this type of exposure.

Urgent medical consultation is also required if any local symptoms like eye pain, changes in vision, or continued irritation occur, or if the initial symptoms worsen or persist for more than 72 hours. These explicit instructions define the circumstances under which regulatory authorities state medical help is necessary.

Therapeutic Uses of Sanlein 0.1

What Sanlein 0.1 Treats: Main Uses and Benefits

Sanlein 0.1 is considered relevant for symptomatic support across several therapeutic domains involving ocular surface discomfort and tear film instability. Sodium Hyaluronate eye drops are commonly used as lubricating eye drops for dry eyes, which supports its application in managing chronic ocular discomfort.

The solution is commonly used to help with symptoms related to inflammatory or irritative states. This includes managing symptoms associated with Chronic Dry Eye Syndrome and related systemic conditions like Sjögren's syndrome. It is also relevant for addressing keratoconjunctival epithelial disorders caused by trauma or other topical medications.

“The goal is to support the eyes during episodes of heightened discomfort related to physical discomfort,” summarizes the therapeutic focus.

Managing Symptom Clusters

The solution is applied in clinical settings that involve recurrent or episodic manifestations, such as persistent ocular dryness, burning, scratchiness, and the foreign body sensation. It assists with maintaining functional stability and supports comfort during surface recovery, including during post-surgical phases or while managing symptoms related to contact lens wear.

Quick Fact: Relief for Abrasive Discomfort
Sanlein 0.1 is generally applied when symptoms are related to physical friction on the ocular surface, contributing to improved comfort during symptomatic periods.

This patient-focused solution contributes to sustained lubrication that may assist in easing the overall symptom load and supports general well-being during symptomatic phases.

Regulatory References

  1. NHS guidance on Sodium Hyaluronate 0.2% Eye Drops

Eligibility and Restrictions for Use

This section outlines the official population eligibility and exclusion criteria for Sanlein 0.1 (Sodium Hyaluronate Ophthalmic Solution 0.1%) based strictly on government regulatory documents.

Classification Eligibility Status Basis for Restriction
Contraindicated Must not use Known hypersensitivity (allergy) to sodium hyaluronate or any other component in the formulation.
Paediatric Patients (Children/Adolescents) Use Not Established Insufficient clinical data or experience to recommend use; use is conditional upon specialist consultation.
Pregnancy/Lactation Conditional Use Human data are limited or insufficient. Use requires professional consultation and a risk-benefit assessment, despite negligible systemic absorption.
Soft Contact Lens Users Restricted Use The preservative (e.g., benzalkonium chloride) in some formulations may be adsorbed by soft contact lenses. Lenses must be removed before application and reinserted after the time specified in the label (typically 15 minutes).

General adult users without documented allergies are allowed to use the medicine as indicated. Eligibility is defined by the absence of allergy and the conditional management of special populations, reflecting the drug's minimal systemic risk but mandatory local precautions and data limitations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding Sanlein 0.1 (Sodium Hyaluronate Ophthalmic Solution) indicates an absence of explicitly documented drug-drug interactions with other systemic or topical medications in the relevant sections of authoritative labeling.

Interaction Profile Summary

The formulation, which is an ophthalmic solution containing the substance sodium hyaluronate, has not been associated with known or clinically significant interactions that require specific restrictions in co-administration with other medicines. This status is typically reflected in the official product labeling, which often omits a dedicated section for drug interactions, or explicitly states that none are known.

Consequently, no specific medicinal product classes, individual drugs, or substance categories are formally listed in official government documents as being restricted or contraindicated for use with Sanlein 0.1.

Interaction Context Constraints

Interaction Domain Official Regulatory Status
Interacting Prescription Drugs/Classes None explicitly noted or restricted
Over-the-Counter (OTC) Drugs/Supplements None explicitly noted or restricted
Timing-based Administration Rules No specific timing constraints noted due to drug interaction

This interaction profile structure, where no moderate or minor drug interactions are explicitly noted, establishes the regulatory context for the use of Sanlein 0.1, indicating a low potential for pharmaceutical interactions based on available regulatory data.

Mechanism of Action

The function of Sanlein 0.1 (Sodium Hyaluronate) involves a dual mechanism, encompassing essential physicochemical effects for lubrication and specific biological signaling for tissue organization.

Viscoelasticity and Ocular Friction Modulation

The active ingredient possesses pseudoplasticity, meaning its high viscosity changes dynamically with movement. At rest, the high-molecular-weight polymer forms a cushion-like layer on the ocular surface. During the blink cycle (high shear force), the viscosity temporarily drops. This physical state establishes a low-shear interface that limits mechanical force on the epithelial cells, thereby modulating the friction exerted on the corneal and conjunctival surfaces.

Mucoadhesion and Tear Film Stabilization

Sodium Hyaluronate is a humectant due to its capacity to bind and hold a large volume of water molecules. This inherent ability, coupled with strong mucoadhesion (adherence to the eye's mucus layer), creates a stable, water-rich hydrogel that coats the epithelium. This mechanism prolongs the solution’s residence time on the eye and directly affects tear film stabilization and water retention.

Cellular Signaling and Epithelial Motility

Beyond its physical role, the high-molecular-weight molecule acts as a biological ligand that binds to specific cell surface receptors, notably the CD44 receptor on the ocular epithelium. This interaction modulates the cell's underlying activity, promoting the motility and migration of epithelial cells, a function that is integral to the tissue's intrinsic repair pathway.

Dosage and Administration Information

Administration Procedure

Proper administration of Sanlein 0.1 involves a specific sequence of steps to ensure the solution is applied effectively to the ocular surface.

Preparation

Before applying the eye drops, hands should be washed thoroughly with soap and water. If contact lenses are worn, they should be removed prior to using the drops, as certain components of the solution may interact with lens materials.

Application Technique

  1. Positioning: Tilt the head back slightly or lie down and look upward.
  2. Creating a Pocket: Use one finger to gently pull down the lower eyelid, creating a small pocket between the eyelid and the eye.
  3. Positioning the Bottle: Hold the dropper bottle upside down near the eye. Care must be taken to ensure the tip of the dropper does not touch the eye, eyelashes, eyelids, or any other surface to prevent contamination of the remaining solution.
  4. Dispensing the Drop: Gently squeeze the bottle to release the required number of drops into the lower eyelid pocket.
  5. Closing the Eye: Close the eye gently for a brief period. To help the solution remain on the ocular surface, light pressure can be applied to the inner corner of the eye (near the nose) to temporarily block the tear duct.

Post-Application

Any excess liquid on the skin should be wiped away with a clean tissue. If multiple types of eye drops are being used, a specific interval should be maintained between the applications of different products to prevent the second drop from washing out the first. The cap should be replaced tightly on the bottle immediately after use.

Recent Clinical Evidence

Sanlein 0.1: Overview of Clinical Evidence

The research landscape for 0.1% Sodium Hyaluronate ophthalmic solution is based primarily on Randomized Controlled Trials (RCTs) and systematic reviews. These studies have explored the solution's role in conditions involving ocular surface discomfort, maintaining a strictly descriptive, non-advisory summary of the evidence.

Evidence for Chronic Dry Eye Syndrome (DED)

The solution was largely evaluated in comparative studies involving adults who were often stratified by disease severity groups with Chronic Dry Eye Syndrome. Studies examined two main types of outcomes: patient-reported outcomes (such as the Ocular Surface Disease Index or OSDI) to describe perceived discomfort, and objective clinical signs to monitor the functional layer of the tear film (e.g., Tear Film Break-Up Time or TBUT).

Research reports how symptoms evolved in the observed populations and describes measured patterns when compared against non-active solutions, such as saline. The results apply only to the specific populations studied, and evidence quality varies across studies when compared to other active treatments.

Research for Epithelial Disorders and Uncertainty

Comparative trials have also explored the solution’s use in patients with keratoconjunctival epithelial disorders—conditions involving damage to the eye’s surface due to trauma or other factors. In these research scenarios, studies monitored outcomes related to the physical integrity and healing of the eye’s outer layer, providing insight into short-term changes.

Long-term outcomes are not well characterized, as most clinical trials featured follow-up durations that were limited to three months or less. Data for certain groups remain insufficient, including evidence for pediatric patients. Furthermore, comparative evidence is lacking for a clear statement regarding the relative performance of the 0.1% solution against every other active tear substitute.

Frequently Asked Questions (FAQ)

Common questions about Sanlein 0.1 (FAQ)

Q: How many times a day do people typically use Sanlein 0.1?

Regulatory documentation states that one drop is usually instilled five to six times daily. The prescribing physician may adjust the dosage based on the individual patient's symptoms and condition severity.

Q: Do I need to take out my contact lenses before applying Sanlein 0.1?

Official documentation indicates that hydrogel soft contact lenses should be removed before using the drops. This precaution is necessary because the preservative (Benzalkonium chloride) in the solution may be adsorbed by the lens material.

Q: What should I do if I think I'm reacting badly to Sanlein 0.1?

Due to the documented potential for a severe hypersensitivity (allergic) reaction, official guidance related to documented adverse reactions indicates the importance of discontinuing use and seeking advice from a medical professional immediately.

Q: Is Sanlein 0.1 described as having regenerative properties?

The documented pharmacological action of the solution includes supporting epithelial cell adhesion and extension, which is integral to the tissue's repair pathway. Non-human studies have further described that the solution can accelerate corneal wound healing.

Q: How does Sanlein 0.1 compare to regular artificial tears?

Sanlein 0.1 is officially described as a viscoelastic agent, which is a functional property that distinguishes it from simpler, non-viscoelastic tear substitutes. Research has examined its stabilizing effect and compared its efficacy against non-Sodium Hyaluronate preparations.

Q: Is Sanlein 0.1 the same as other hyaluronic acid eye drops?

The formulation of Sanlein 0.1 is specifically emphasized in its regulatory information as a viscoelastic agent with a 0.1% concentration. Studies have shown that the effects and performance of different Sodium Hyaluronate concentrations can vary, meaning not all HA drops are considered identical.

Q: What is the main difference between the 0.1% and 0.3% concentrations (if applicable)?

Official product information confirms that both 0.1% (1 mg/mL) and 0.3% (3 mg/mL) concentrations of the solution exist. Clinical studies have been conducted to compare the effects, and research indicates differences in the observed signs of improvement between the two concentrations.

Q: What are the key findings from the major clinical trials on Sanlein 0.1?

Clinical trial summaries indicate that the solution was effective in improving both the objective signs (like corneal staining) and subjective symptoms (like discomfort) of dry eye in the patient populations studied. The safety profile for the solution, as described in regulatory summaries, focuses on localized reactions.

Q: Is it safe to drive immediately after using Sanlein 0.1?

Official safety documentation lists temporary changes to vision, such as blurred vision or irritation, as possible adverse reactions. Because these temporary visual effects may occur, caution is noted regarding the operation of machinery or driving immediately after application.

Q: Do different brands of hyaluronic acid drops use the same formulation as Sanlein 0.1?

Official labeling for Sanlein 0.1 emphasizes its formulation as a viscoelastic agent, a property that creates a stable, protective cushion on the eye's surface. This viscoelastic nature is a key differentiating feature when compared to simpler solutions or other brands.

Q: How is Sanlein 0.1 different from eye drops used for allergies?

Sanlein 0.1 is officially classified as a viscoelastic agent and an ophthalmic lubricant, meaning its primary role is to protect, lubricate, and moisturize the eye's surface. This is a different pharmacological action than that of drops used to treat allergies (e.g., antihistamines).

Q: Are there any known ingredients in Sanlein 0.1 that are animal-derived?

The official labeling describes the active ingredient, Sodium Hyaluronate, as a biotechnologically derived polymer. This description refers to the method of its preparation.

Q: Is Sanlein 0.1 associated with any weight gain or systemic side effects?

Official safety information focuses on localized eye reactions and adverse effects at the administration site. The drug is noted for its negligible systemic absorption, which is why systemic side effects like weight gain are not typically listed in the product's safety profile.

Q: Is Sanlein 0.1 approved for all types of dry eye conditions?

Regulatory approval is specifically for the treatment of keratoconjunctival epithelial disorders. This includes conditions resulting from specific intrinsic diseases (like Sjögren's syndrome) or extrinsic factors such as trauma, surgery, drug use, or contact lens wear.

How should Sanlein 0.1 be stored and disposed of?

Storage Conditions and Stability

The ophthalmic solution must be stored strictly at controlled room temperature, typically defined as between 1 C and 30 C. It is an explicit regulatory requirement that the solution must not be frozen.

To preserve the product's quality, it must be protected from both direct sunlight and moisture, and the container must be kept tightly closed. The medicine must always be stored out of the sight and reach of children.

Post-Opening and Disposal Rules

Official labeling mandates that the solution be discarded after a defined period once opened, which is typically one month (4 weeks), though some specific formulations may allow up to 8 weeks. Single-dose units must be used immediately and never stored or reused.

Unused or expired product must not be disposed of casually. Users are directed to ask a pharmacy or medical institution for instructions on the proper disposal of any remaining solution.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sanlein 0.1 found in:

A-Z Index: